Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug

August 7, 2024

https://www.globenewswire.com/news-release/2024/08/06/2925083/0/en/Clearmind-Medicine-New-Scientific-Publication-Shows-MEAI-s-Potential-as-a-Novel-Weight-Loss-Drug.html

Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.